Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti-CD20 Antibody for the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
2018
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
101
References
0
Citations
NaN
KQI